trimetrexate has been researched along with Cancer of Ovary in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We determined the cytotoxicity of methotrexate and the lipid-soluble antifolate trimetrexate to various human carcinoma cells and their doxorubicin-resistant sublines." | 7.67 | Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. ( Assaraf, YG; Molina, A; Schimke, RT, 1989) |
| " We determined the cytotoxicity of methotrexate and the lipid-soluble antifolate trimetrexate to various human carcinoma cells and their doxorubicin-resistant sublines." | 3.67 | Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. ( Assaraf, YG; Molina, A; Schimke, RT, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Assaraf, YG | 1 |
| Molina, A | 1 |
| Schimke, RT | 1 |
1 other study available for trimetrexate and Cancer of Ovary
| Article | Year |
|---|---|
Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line; Drug Resistance; Female; Gen | 1989 |